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Lab Resource: Multiple Stem Cell Lines - template 
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Abstract:  
Fibroblasts from a patient with Aicardi Goutières Syndrome (AGS) carrying a compound heterozygous 
mutation in TREX1, were reprogrammed into induced pluripotent stem cells (iPSCs) to establish isogenic clonal 
stem cell lines: UNIBSi006-A, UNIBSi006-B, and UNIBSi006-C. Cells were transduced using the episomal Sendai 
viral vectors, containing human OCT4, SOX2, c-MYC and KLF4 transcription factors. The transgene-free iPSC 
lines showed normal karyotype, expressed pluripotent markers and displayed in vitro differentiation potential 
toward cells of the three embryonic germ layers. 
 
Resource Table:  
Unique stem cell lines identifier 
 
UNIBSi006-A 
UNIBSi006-B 
UNIBSi006-C 
Alternative names of stem cell lines AGS1_MM_C12 (UNIBSi006-A) 
AGS1_MM_C13 (UNIBSi006-B) 
AGS1_MM_C14 (UNIBSi006-C) 
Institution A. Nocivelli Institute for Molecular Medicine, Department of 
Molecular and Translational Medicine, University of Brescia, 
25123 Brescia, Italy 
Contact information of distributor Rosalba Monica Ferraro:  rosalbamonica.ferraro@gmail.com 
Type of cell lines iPSCs 
Origin Human  
Additional origin info Age: 5 
Sex: male 
Ethnicity: Caucasian 
Cell Source  Fibroblasts 
Clonality Clonal 
Method of reprogramming CytoTune™-iPS 2.0 Sendai Reprogramming Kit (ThermoFisher 
Scientific). The episomal reprogramming vectors include the 
four Yamanaka factors OCT4, SOX2, KLF4, and C-MYC 
Multiline rationale  Isogenic clones of same disease mutation 
Gene modification YES 
Type of modification Hereditary 
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Associated disease  Aicardi Goutières Syndrome 
Gene/locus TREX1  
Method of modification N/A 
Name of transgene or resistance N/A 
Inducible/constitutive system N/A 
Date archived/stock date Jan-2017 
Cell line repository/bank https://hpscreg.eu/user/cellline/edit/UNIBSi006-A 
https://hpscreg.eu/user/cellline/edit/UNIBSi006-B 
https://hpscreg.eu/user/cellline/edit/UNIBSi006-C 
Ethical approval IRB Spedali Civili and University of Brescia, NP n.1603 -Studio 
AGS-CARIPLO 
 
Resource utility  
Aicardi Goutières syndrome (AGS) is a rare early-onset monogenic inflammatory encephalopathy. Considering 
the unavailability of patients’ neuronal bioptic materials, the most suitable in vitro model is represented by 
iPSCs as a useful instrument to achieve patient-specific neuronal cells. 
 
Resource Details  
AGS is a severe inflammatory encephalopathy, typically showing different degrees of neurological impairment, 
elevated cerebrospinal fluid (CSF) interferon-α (IFN-α) level and specific neuroradiologic features, with onset 
in early infancy [1]. AGS is a genetically heterogeneous disorder, involving mutations in different anti-viral 
genes related to nucleic acid processing. The first causative gene identified in AGS encodes for the Three-
prime Repair Exonuclease 1 (TREX1) active against the single strand DNA and the nicked strand of double-
stranded DNA. AGS type 1 (AGS1) is characterized by biallelic mutations in TREX1 [2]. 
In this study we generated and characterized three isogenic iPSC clones derived from fibroblasts of a 5 years 
old male affected by AGS with the compound heterozygous mutation 
TREX1:NM_033629.6:c.[260insAG];[290G>A]:p.[S88fs*22];[R97H] [3]. This patient shows typical clinical 
features of AGS1 as microcephaly, chilblains-like lesions, severe tetraparesis, cerebral calcifications, 
leukodystrophy and raised CSF IFN-α [3]. 
Fibroblasts were reprogrammed using the CytoTune-iPS 2.0 Sendai Reprogramming Kit, in feeder free 
condition. This kit utilizes a modified form of Sendai virus as episomal vector to introduce the Yamanaka's 
factors OCT4, SOX2, KLF4, and c-MYC into somatic cells. At day 20  post-transduction, several individual and 
isolate iPSC colonies were manually picked and expanded. After generation of a frozen stock for 10 different 
iPSC clones, 3 clones that best display an ESC-like morphology (Supplementary Fig.1) were chosen for further 
expansion and characterization: UNIBSi006-A, UNIBSi006-B, and UNIBSi006-C. 
We verified that these iPSC lines were mycoplasma-free (Supplementary Fig.2) and we confirmed the 
presence of the patient mutations by Sanger sequencing (Fig.1A). The iPSC lines were authenticated against 
the parental fibroblast lines via short tandem repeat (STR) profiling (available with the authors). The selected 
clones showed a normal karyotype (46,XY), assessed at different passages (passage 12, 25, and 42), confirming 
the cytogenetic stability in culture (Fig. 1B). 
The expression of pluripotent markers was examined by immunostaining using antibodies against human Tra-
1-60, properly localized on cell surface, and the transcriptional factor OCT4 expressed at nuclear level (Fig.1C). 
To deepen the pluripotency characterization, passage 10 UNIBSi006-A, passage 16 UNIBSi006-B, and passage 8 
UNIBSi006-C iPSCs were subjected to TaqMan® Human Pluripotent Stem Cell Scorecard™ analysis. Each line 
showed a positive score for self-renewal gene expression and a negative score for expression of genes 
involved in ectodermal, mesodermal, and endodermal formation. Furthermore, no residual Sendai virus was 
detected. Only UNIBSi004-B showed a borderline score for ectodermal gene expression that has been 
considered within the standard deviation range of acceptability to be a pluripotent iPSC line (Fig.1D).  
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Finally, we tested the spontaneous capacity of iPSC clones to differentiate in vitro into three embryonic germ 
layers. In order to obtain a deeper analysis on a broad spectrum of genes, one clone, the UNIBSi006-A, was 
analyzed through TaqMan® Human Pluripotent Stem Cell Scorecard™ showing the expected result (Fig.1E). 
The remaining clones, UNIBSi006-B, and UNIBSi006-C, were evaluated by quantitative PCR (qPCR) for 
ectodermal, mesodermal and endodermal markers (PAX6-SOX1, NCAM1/CXCR4-ACTA2, GATA4-SOX17, 
respectively) (Fig.1F).  
 
Materials and Methods  
 
Fibroblasts reprogramming  
Primary fibroblasts, derived from AGS1 patient’s skin biopsy, were cultured in DMEM with 10% Fetal Bovine 
Serum, 1% L-Glutamine, and 1% Penicillin/Streptomycin (Euroclone) at 37 °C in 5% CO2. For iPSCs generation 
100.000 fibroblasts at 60% of confluence were transduced using the CytoTune-iPS 2.0 Sendai Reprogramming 
Kit (ThermoFisher Scientific) following manufacturer's instructions. At day 8 post-transduction, cells were 
seeded onto a Matrigel (Corning) -coated culture dish and the next day medium was changed to Nutristem 
hPSC XF medium (Biological-Industries). After 20 days, colonies positive to Tra-1-60 staining, were manually 
picked to further expansion and characterization. iPSCs were fed daily with Nutristem hPSC-XF Medium, and 
manually picked every 5 days on new Matrigel-coated well plate with 1:2 ratio. 
 
Sequencing 
DNA was extracted using the QIAmp DNA Blood Mini Kit (Qiagen), and amplified by PCR using AmpliTaq Gold® 
DNA Polymerase (ThermoFisher Scientific) with TREX1 primers (Table 3) using the GeneAmp PCR System 9700 
(Applied Biosystem) following these PCR cycle parameters: initial denaturation at 95°C for 12min, 
denaturation at 94°C for 30 sec, annealing at 60°C for 30 sec, extension at 72°C for 30 sec, final extension at 
72°C for 7 min. Number of cycles: 38. Sequencing reactions were performed using BigDye Terminator v1.1 
Cycle Sequencing Kit following manufacturer protocol: incubation at 94°C for 5 min, denaturation at 94°C for 
10 sec, annealing at 60°C for 5 sec, extension at 60°C for 2min and 30 sec. Number of cycles: 25. The purified 
sequencing reactions were run using Prism 3130 Genetic Analyzer (ThermoFisher Scientific) and analysed 
using SeqScape v3.0 Software. 
 
Karyotyping 
Passage 12, 25, and 42 iPSCs undergoing active cell division were blocked at metaphase by 10μg/ml of 
colcemid for 3h (KaryoMax, Gibco Co. BRL), detached from the growth surface by trypsin–EDTA, and 
subsequently swollen by exposure to hypotonic KCl (0.075M) solution for 7min at 37°C. Cells were fixed with 
methanol/glacial acetic acid (3:1) three times, and dropped onto glass slides. Cytogenetic analysis was 
performed using conventional QFQ-banding at 450 bands resolution according to the International System for 
Human Cytogenetic Nomenclature (ISCN 2016). A minimum of 20 metaphase spreads were analysed for each 
samples and karyotyped using a chromosome imaging analyzer software (Chromowin software, Tesi Imaging). 
TaqMan hPSC scorecard assay 
RNAs were extracted using NucleoSpin® RNA II kit (Macherey-Nagel) following instructions. 1µg of RNA 
collected from each iPSCs were sent to ThermoFisher Scientific CellModel Service to perform TaqMan hPSC 
scorecard assay. This test was used to verify the loss of Sendai virus, and to evaluate the expression levels of 
genes involved in self-renewal, endoderm, mesoderm, and ectoderm development.  
Immunofluorescence staining  
iPSCs were fixed and permeabilized using Fix&Perm-Reagent kit (SIC). Then, blocking solution iBindTM Buffer 
(Invitrogen) was applied for 45min. Primary and secondary antibodies, diluted in blocking solution, were 
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added and incubated for 3 and 1 h respectively, at room temperature (RT). The antibodies used are 
summarized in Table 3. Cellular nuclei were counterstained with Hoechst 33342 (ThermoFisher Scientific). 
Cells were observed with an inverted fluorescence microscope (Olympus IX70), and images were analysed 
with the Image-Pro Plus software v7.0 (Media Cybernetics). 
 
In vitro trilineage differentiation  
iPSCs were dissociated into single-cell suspension and seeded on Matrigel-coated 24-well plates (105, 0.8x105, 
1.3x105 cells for ectoderm, mesoderm, and endoderm, respectively) in the specific medium according to the 
StemMACSTM Trilineage Differentiation Kit protocol (MACS Miltenyi Biotec). Seven days later, cells were 
collected for RNA extraction and qPCR of lineage specific markers was performed. Only for UNIBSi006-A, RNA 
collected from each germinal layers differentiation was mixed in a 1:1:1 ratio to perform TaqMan hPSC 
scorecard assay. 
 
RNA extraction and qPCR  
Total RNAs were extracted using NucleoSpin® RNA II kit (Macherey-Nagel) and quantified by a 
Spectrofluorometer. RNAs were retro-transcribed by ImPromII™ Reverse Transcription System (Promega), 
following the protocol. qPCR for iPSCs differentiation capacity was performed using iQ MPLX powermix and 
TaqMan Probe based assays. Probes are listed in Table 3. Assays were performed on CFX96 C1000 Touch™ 
Real-Time PCR Detection System, and analysed with CFX manager software v.3.1 (BioRad). The relative 
quantification of target genes was calculated by the 2^− ΔΔCt method, using βACTIN as housekeeping gene. 
 
Mycoplasma detection 
The absence of mycoplasma contamination was confirmed using a standard PCR to amplify the 16Sr RNA of 
the genus Mycoplasma from the supernatant of confluent cell culture and positive controls. The amplification 
was performed with AmpliTaq Gold™ DNA Polymerase (ThermoFisher Scientific) using the GeneAmp PCR 
System 9700 (Applied Biosystem) with PCR cycle parameters described as above. Primers used are listed in 
Table 3. 
 
STR analysis 
DNAs from parental fibroblasts and iPSC clones were extracted as above, and amplified with AmpFlSTR® 
Identifiler® Plus (LifeTechnologies) following instructions. 
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Table 1: Summary of lines 
 
iPSC line Abbreviation in Gender Age Ethnicity Genotype Disease 
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names figures of locus 
 
UNIBSi006-A UNIBSi006-A Male 5 y Caucasian -/AG 
G/A 
Aicardi 
Goutières 
Syndrome 
type 1 
(AGS1). 
UNIBSi006-B UNIBSi006-B Male 5 y Caucasian -/AG 
G/A 
Aicardi 
Goutières 
Syndrome 
type 1 
(AGS1). 
UNIBSi006-C UNIBSi006-C Male 5 y Caucasian -/AG 
G/A 
Aicardi 
Goutières 
Syndrome 
type 
1(AGS1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Characterization and validation 
 
Classification Test Result Data 
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Morphology  Photography 
 
normal Supplementary Figure 1 
Phenotype Qualitative analysis: 
immunocytochemistry 
Positive for  OCT4, and 
TRA-1-60 expression 
Figure 1 panel  C 
Quantitative analysis: 
TaqMan® Human 
Pluripotent Stem Cell 
Scorecard™ analysis 
Positive score for self-
renewal gene expression 
and a negative score for 
ectodermal, mesodermal, 
and endodermal gene 
expression. 
Figure 1 panel  D 
Genotype Karyotype (Q-banding) 
and resolution 
46,XY 
Resolution 450-500 
Figure 1 panel B 
Identity 
  
Microsatellite PCR 
(mPCR) OR 
STR analysis 
 
N/A N/A 
16 distinct loci: all matched 
to parental cell line  
Available with the 
authors 
Mutation analysis (IF 
APPLICABLE) 
  
Sequencing Compound heterozygous 
mutation: 
c.[260insAG];[290G>A]. 
Figure 1 panel A 
Southern Blot OR WGS  N/A  N/A 
Microbiology and 
virology 
Mycoplasma  
 
Negative Supplementary Figure 2 
Differentiation potential Direct differentiation into  
three germ layers 
UNIBSi006-A: TaqMan® 
hPSC Scorecard™ analysis; 
negative score for self-
renewal  gene expression 
and positive score for 
trilineage gene expression 
Figure 1 panel E 
UNIBSi006-B and 
UNIBSi006-C: relative gene 
expression of PAX6-SOX1 
(Ectoderm), NCAM1/CXCR4 
–ACTA1 (Mesoderm), and 
GATA4-SOX17 (Endoderm). 
Figure 1 panel F 
Donor screening 
(OPTIONAL) 
HIV 1 + 2 Hepatitis B,  
Hepatitis C 
N/A  N/A 
Genotype additional 
info (OPTIONAL) 
Blood group genotyping N/A N/A 
HLA tissue typing N/A N/A 
  
Journal Pre-proof
Jo
urn
al 
Pr
e-p
roo
f
Table 3: Reagents details 
 
Antibodies used for immunocytochemistry/flow-cytometry 
  Antibody Dilution Company Cat # and RRID  
Pluripotency Markers Rabbit anti-OCT4 1:400 Thermo Fisher Scientific, Cat# A-
13998. RRID: AB_2534182 
Pluripotency Markers Mouse anti-TRA-1-60 1:100 Thermo Fisher Scientific, Cat# 
4110000. RRID: AB_2533494 
Secondary antibodies Goat anti rabbit IgG (H+L) 
Alexa Fluor 568 
1:300 Thermo Fisher Scientific, Cat# A-
11011. RRID: AB_143157 
Secondary antibodies Goat anti mouse IgG 
(H+L) Alexa Fluor 488 
1:300 Thermo Fisher Scientific, Cat# A-
11001. RRID: AB_2534069 
 
Primers  for PCR assay 
 Target Forward/Reverse primer (5′-3′) 
Mutation sequencing TREX1 (200bp) ACAAGCTCTCCCTGTGTGTG/ 
GAAGTCGTAGCGGTCACCAT  
Mycoplasma detection 16s rRNA (268bp) GGGAGCAAACAGGATTAGATACCCT/ 
TGCACCATCTGTCACTCTGTTAACCTC 
 
Differentiation RT-qPCR assays with TaqMan chemistry 
 Target Probe 
 Ectoderm PAX6 Hs.PT.58.25914558 
SOX1 Hs.PT.58.28041414.g 
 Mesoderm ACTA2 Hs.PT.56a.2542642 
NCAM1 Hs.PT.58.39694135 
CXCR4 Hs00607978_s1 
Endoderm GATA4 Hs.PT.58.259457 
SOX17 Hs.PT.58.24876513 
Housekeeping gene ACTB Hs.PT.39a.22214847 
 
Figure 1 
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